Please use this identifier to cite or link to this item:
Title: Prostate cancer immunology - an update for Urologists.
Austin Authors: Rajarubendra, Nieroshan;Lawrentschuk, Nathan;Bolton, Damien M ;Klotz, Laurence;Davis, Ian D
Affiliation: Department of Surgery, University of Melbourne, Austin Hospital, Urology Unit, Australia
Issue Date: 10-Nov-2010
Publication information: BJU International 2010; 107(7): 1046-51
Abstract: A better understanding of the immune processes in the pathogenesis and progression of prostate cancer (CaP) may point the way towards improved treatment modalities. The challenge is to amplify immune responses to combat tumour escape mechanisms. Infection and inflammation may have a role in prostate carcinogenesis, including the newly discovered xenotropic murine leukaemia virus (XMRV). These inflammatory states damage defence mechanisms and induce a high proliferative state favouring further mutation and impaired immune surveillance. With this knowledge we are able to explore the use of immunotherapy to rejuvenate the immune system in combating CaP. Recently Sipuleucel-T, an immunotherapeutic agent for metastatic androgen independent CaP, has resulted in improved survival and might be the first immunotherapeutic agent to obtain approval for CaP treatment. This short review will focus on the growing body of evidence suggesting an immunity-based link between CaP and inflammation and infection.
Gov't Doc #: 21070575
DOI: 10.1111/j.1464-410X.2010.09820.x
Journal: BJU International
Type: Journal Article
Subjects: Cancer Vaccines.therapeutic use
Epidemiologic Methods
Prostatic Neoplasms.immunology.therapy
Tissue Extracts.therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 17, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.